Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 204

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 7
Chunk 204
---
Legal Fees include expenses for corporate, patent and trademark fees with outside law firms.

•Audit Fees consist of fees billed for professional services rendered for the audit of our annual financial statements, review of our interim financial statements, comfort and consent letters.

•Consulting services provided by non-employees for general and administrative tasks, includes accounting, tax, human resources, finance, investor relations, board compensation, and internet support.

•Insurance includes directors and officers’ insurance, workers compensation insurance, product liability insurance, business insurance, employee and cyber liability insurance.

•Other includes facility expenses, office supplies, computer related costs, public relations costs, recruiting costs and conferences.

•Stock-based Compensation relates to stock options granted to our employees and board members and warrants granted to our independent consultants who work in the general and administrative aspects.

Other income and expenses

We earned interest income on our cash balances and investments in U.S. Treasury bills.

86

We incurred interest expense on our convertible notes through June 29, 2023. Accrued interest was converted into Common Stock upon commencement of our IPO.

Results of Operations

The following tables summarize our results of operations for the years ended December 31, 2024 and 2023 (in thousands):

Years Ended December 31,20242023ChangeOperating expenses:Research and development$10,496 $4,786 $5,710 General and administrative6,089 3,533 2,556 Total operating expenses16,585 8,319 8,266 Loss from operations(16,585)(8,319)(8,266)Interest income314 324 (10)Interest expense- (305)305 Loss on debt extinguishment- (2,262)2,262 Other income, net3 24 (21)Net loss$(16,268)$(10,538)$(5,730)Preferred stock deemed dividend- (1,324)1,324 Net loss attributable to common stockholders$(16,268)$(11,862)$(4,406)

Years Ended December 31,20242023ChangeResearch and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$(128)$984 $(1,112)INVINCIBLE-2 Study (Phase 2 Breast)233 402 (169)INVINCIBLE-3 Study (Phase 3 Sarcoma)6,225 578